Cargando…
Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies
Assessment of specific antibody (Ab) production to polysaccharide antigens is clinically relevant, identifying patients at risk for infection by encapsulated bacteria and thus enabling a more rigorous selection of patients that can benefit of immunoglobulin replacement therapy. Classically, the gold...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289764/ https://www.ncbi.nlm.nih.gov/pubmed/32551240 http://dx.doi.org/10.1016/j.mex.2020.100936 |
_version_ | 1783545524854456320 |
---|---|
author | Ochoa-Grullón, J. Orte, C. Rodríguez de la Peña, A. Guevara-Hoyer, K. Cordero Torres, G. Fernández-Arquero, M. Serrano-García, I. Recio, M.J. Pérez de Diego, R. Sánchez-Ramón, S. |
author_facet | Ochoa-Grullón, J. Orte, C. Rodríguez de la Peña, A. Guevara-Hoyer, K. Cordero Torres, G. Fernández-Arquero, M. Serrano-García, I. Recio, M.J. Pérez de Diego, R. Sánchez-Ramón, S. |
author_sort | Ochoa-Grullón, J. |
collection | PubMed |
description | Assessment of specific antibody (Ab) production to polysaccharide antigens is clinically relevant, identifying patients at risk for infection by encapsulated bacteria and thus enabling a more rigorous selection of patients that can benefit of immunoglobulin replacement therapy. Classically, the gold-standard test is the measurement of antibody production to pure polysaccharide pneumococcal (PPV) immunization. Several factors, including introduction of conjugate vaccination schedule, serotyping analysis, high baseline Ab levels, have hindered the evaluation of polysaccharide antigens. This is even more difficult in secondary immunodeficiencies (SID), where patients can show secondary responses despite lack of primary antibody responses and present with recurrent or severe infections. Assessment of specific Ab production to pure Salmonella typhi Vi polysaccharide (TV) immunization has been proposed as a complementary test to PPV, given its low seroprevalence. To set the optimal cut-off value for PPV and TV response in SID, we tested different biostatistical methodologies, including ROC analysis, Youden index, Union index and Closest-topleft in a cohort of 42 SID patients and 24 healthy controls. The statistically chosen cut-offs value pre-post TV Ab ratio was ≥5, (sensitivity of 90%, specificity of 100%) and a postvaccination TV concentration of 28.5 U/mL (sensitivity of 90%, specificity of 95%), showing relevant clinical correlate. |
format | Online Article Text |
id | pubmed-7289764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72897642020-06-17 Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies Ochoa-Grullón, J. Orte, C. Rodríguez de la Peña, A. Guevara-Hoyer, K. Cordero Torres, G. Fernández-Arquero, M. Serrano-García, I. Recio, M.J. Pérez de Diego, R. Sánchez-Ramón, S. MethodsX Immunology and Microbiology Assessment of specific antibody (Ab) production to polysaccharide antigens is clinically relevant, identifying patients at risk for infection by encapsulated bacteria and thus enabling a more rigorous selection of patients that can benefit of immunoglobulin replacement therapy. Classically, the gold-standard test is the measurement of antibody production to pure polysaccharide pneumococcal (PPV) immunization. Several factors, including introduction of conjugate vaccination schedule, serotyping analysis, high baseline Ab levels, have hindered the evaluation of polysaccharide antigens. This is even more difficult in secondary immunodeficiencies (SID), where patients can show secondary responses despite lack of primary antibody responses and present with recurrent or severe infections. Assessment of specific Ab production to pure Salmonella typhi Vi polysaccharide (TV) immunization has been proposed as a complementary test to PPV, given its low seroprevalence. To set the optimal cut-off value for PPV and TV response in SID, we tested different biostatistical methodologies, including ROC analysis, Youden index, Union index and Closest-topleft in a cohort of 42 SID patients and 24 healthy controls. The statistically chosen cut-offs value pre-post TV Ab ratio was ≥5, (sensitivity of 90%, specificity of 100%) and a postvaccination TV concentration of 28.5 U/mL (sensitivity of 90%, specificity of 95%), showing relevant clinical correlate. Elsevier 2020-05-29 /pmc/articles/PMC7289764/ /pubmed/32551240 http://dx.doi.org/10.1016/j.mex.2020.100936 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Immunology and Microbiology Ochoa-Grullón, J. Orte, C. Rodríguez de la Peña, A. Guevara-Hoyer, K. Cordero Torres, G. Fernández-Arquero, M. Serrano-García, I. Recio, M.J. Pérez de Diego, R. Sánchez-Ramón, S. Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title | Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title_full | Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title_fullStr | Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title_full_unstemmed | Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title_short | Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
title_sort | typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies |
topic | Immunology and Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289764/ https://www.ncbi.nlm.nih.gov/pubmed/32551240 http://dx.doi.org/10.1016/j.mex.2020.100936 |
work_keys_str_mv | AT ochoagrullonj typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT ortec typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT rodriguezdelapenaa typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT guevarahoyerk typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT corderotorresg typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT fernandezarquerom typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT serranogarciai typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT reciomj typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT perezdediegor typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies AT sanchezramons typhimviimmunizationassiststodiscriminateprimaryantibodyresponsesinhematologicalmalignancies |